​​​

​

1. • Dr. Nicholas Vogelzang Discusses Latest Advances in Prostate Cancer - Duration: 2:31.

     ​

   • Dr. Nicholas Vogelzang Discusses Radium-223 in Prostate Cancer - Duration: 1:50.

     ​

   • Nicholas J. Vogelzang, MD, FASCO, FACP, discusses the influence of an AR-V7 commercial test - Duration: 1:34.

     ​

   • What is Targeted Therapy, with Nicholas Vogelzang, MD - Duration: 6:33.

     ​

   • Dr. Nicholas Vogelzang Discusses Sequencing Abiraterone and Enzalutamide - Duration: 1:53.

     ​

   • Nicholas J. Vogelzang, MD, FASCO, FACP, on the practice-changing results of the LATITUDE study - Duration: 0:53.

     ​

   • Dr. Nicholas Vogelzang Discusses PSMA ADC in Prostate Cancer - Duration: 2:55.

     ​

   • ASCO 2013 - Nicholas Vogelzang, MD, discusses Xofigo (radium Ra 223 dichloride) - Duration: 8:35.

     ​

   • What to do with the post-abiraterone/-enzalutamide patient? - Nicholas J. Vogelzang - Duration: 15:42.

     ​

   • Nicholas J. Vogelzang, MD, FASCO, FACP, on treating metastatic prostate cancer with multiple drugs - Duration: 1:09.

     ​

   • Nicholas J. Vogelzang, MD, FASCO, FACP, on immunotherapy and metastatic prostate cancer - Duration: 3:03.

     ​

   • Nicholas J. Vogelzang, MD, FASCO, FACP, discusses the potential of the AR-V7 test - Duration: 1:31.

     ​

   • Nicholas J. Vogelzang, MD, on where chemotherapy fits into treatment for prostate cancer - Duration: 1:41.

     ​

   • Nicholas J. Vogelzang, MD, FASCO, FACP, on metastatic castration-resistant prostate cancer patients - Duration: 1:25.

     ​

   • Nicholas J. Vogelzang, MD, FASCO, FACP, discusses resistance and advanced prostate cancer - Duration: 1:47.

     ​

   • Nicholas J. Vogelzang, MD, FASCO, FACP, considers data from CHAARTED, STAMPEDE, and LATTITUDE - Duration: 2:09.

     ​

   • Nicholas J. Vogelzang, MD, FASCO, FACP, speculates on the cost implications of abiraterone - Duration: 0:48.

   • ​

   • Dr. Vogelzang Describes Cabozantinib's Side Effects - Duration: 1:14. 

   • ​

   • Perspectives in Prostate Cancer - Dr. Nick Vogelzang ASCO 2014 - Duration: 6:11.

   • ​

   • 2013 OncPrac Summit: Nicholas Vogelzang on how he treats metastic prostate cancer - Duration: 5:01.

   •  

   • Dr. Nicholas Vogelzang on First-Line Axitinib Versus Sorafenib in mRCC - Duration: 1:19.

   • ​

   • ​Nicholas J. Vogelzang, MD, FASCO, FACP, explains the influence of CHAARTED and STAMPEDE - Duration: 1:42.

     ​

   • Nicholas J. Vogelzang, MD, FASCO, FACP, on BRCA1 and BRCA2 genetic testing as guidelines - Duration: 1:11.

     ​

   • Mesothelioma Treatment Origins ~ Interview with Dr Vogelzang - Duration: 3:28.

     ​

   • ​Dr. Vogelzang Discusses Mortalities in Cabozantinib Trial - Duration: 1:36.

     ​

   • ​Dr. Vogelzang Discusses the Addition of Chemotherapy to ADT in Men With Prostate Cancer - Duration: 3:07.

     ​

   • ​Nicholas Vogelzang on the Top Cancer Breakthroughs of 2011 - Duration: 8:41.

     ​

   • ​Dr. Vogelzang on Cabozantinib Clinical Trial Results - Duration: 0:56.

     ​

   • ​Nicholas J. Vogelzang, M.D. - 2014 Inspired Excellence Award Recipient | Las Vegas HEALS - Duration: 4:50.

     ​

   • Mesothelioma Symptoms and Risk Factors with Dr. Vogelzang - Duration: 3:24.

     ​

   • ​Mesothelioma Clinical Trial: Interview with Dr. Vogelzang - Duration: 4:31.

     ​

   • about Nicholas Vogelzang - Mesothelioma Attorney - Duration: 1:44.

     ​

   • ​Dr. Vogelzang Discusses the Prostate Health Cocktail - Duration: 0:52.

     ​

   • ​Dr. Vogelzang Reviews Radium-223 in Metastatic Prostate Cancer - Duration: 3:45.

     ​

   • ​Dr. Vogelzang on XL184's Effect on Bone Metastases - Duration: 1:11.

     ​

   • ​Dr. Vogelzang Discusses Treatment With Radium-223 and Chemotherapy for Prostate Cancer - Duration: 1:04.

     ​

   • ​Holiday Healthcare Happy Hour 2015 - Nicholas Vogelzang - Duration: 1:58.

   • ​

   • Utility of PD-L1 as a Biomarker in Bladder Cancer - Duration: 1:32.

   • ​

   • Dr. Vogelzang Discusses Cabozantinib's Dose Size - Duration: 1:45.

   • ​

   • ​Dr. Vogelzang Discusses Cabozantinib Trial Design - Duration: 1:35.

   • ​

   • ​Dr. Vogelzang Discusses the Cabozantinib Trial Design - Duration: 1:34.

   • ​

   • ​Mesothelioma Treatment Origins: Interview with Dr. Vogelzang - Duration: 3:28.

   •  

   • ​Dr. Vogelzang Describes Two Additional Analyses of the ALSYMPCA Trial - Duration: 0:47.

   • ​

   • ​New diagnostics for prostate cancer - Duration: 1:21.

   • ​

   • ​CCCN: Clinical Research - Duration: 2:31.

   • ​

   • ​Dr. Vogelzang Discusses MPDL3280A in Patients with Metastatic Urothelial Bladder Cancer - Duration: 1:12.

   • ​

   • ​Evolving Renal Cell Carcinoma Treatment Paradigm - Duration: 3:25.

   • ​ASCO-GU Meeting Highlights - Duration: 5:35.

   • ​

   • ​Mesothelioma Treatment: Interview with Dr. Vogelzang - Duration: 3:00.

   • ​

   • ​Mesothelioma Chemotherapy, Alternative Treatments, and Surgery: Interview with Dr. Vogelzang - Duration: 2:54

   • ​

   • ​Dr. Vogelzang | 3rd Annual Inspired Excellence in Health Care Awards Gala | Las Vegas HEALS - Duration: 2:02.

   • ​

   • ​New data on Radium 223 presented at ASCO - Duration: 5:05.

   • ​

   • ​Congrats Dr. Vogelzang | 3rd Annual Inspired Excellence in Health Care Awards Gala | Las Vegas HEALS - Duration: 0:32.

   • ​

   • ​Prostate Cancer News from ASCO 2010 - Duration: 10:06.

   • ​

   • Checkpoint Inhibitors Under Exploration in RCC - Duration: 2:00​